Recombinant Proteins Market Report 2025

The recombinant proteins market size has grown rapidly in recent years. It will grow from $2.31 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, rising prevalence of chronic diseases, growing aging population, government initiatives and funding, expanding applications in research and diagnostics.

The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $4.3 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increased adoption of personalized medicine, rapid expansion of the biotechnology sector, global efforts to address rare diseases, advancements in protein engineering techniques, emerging markets, and untapped opportunities. Major trends in the forecast period include expansion of personalized medicine, rapid growth in the biotechnology sector, demand for therapeutic proteins, emergence of novel therapeutic targets, global focus on vaccine development.

The increasing emphasis on personalized medicine is expected to drive the growth of the recombinant protein market in the coming years. Personalized medicine is a medical approach that customizes treatments and therapies based on the unique characteristics, genetics, and needs of each patient, aiming to achieve more effective and targeted healthcare outcomes. The growth of personalized medicine is largely due to advancements in genomic technologies and data analytics, which allow for treatments tailored to individual genetic profiles. Recombinant proteins play a crucial role in personalized medicine by enabling the development of customized therapies that target a patient's specific genetic and molecular profile, enhancing treatment efficacy and minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant rise from the six approvals in 2022. As a result, the growing focus on personalized medicine is contributing to the expansion of the recombinant protein market.

Government initiatives in healthcare research and development are expected to contribute to the growth of the recombinant protein market. Various government authorities are undertaking specific actions and programs to support healthcare initiatives, including research into recombinant proteins. In 2022, the UK government announced £260 million in funding to boost healthcare research and manufacturing, supporting NHS-led health research, diagnostics, and treatment development. Government initiatives for research and development in healthcare play a crucial role in driving the recombinant protein market forward.

Product innovation emerges as a prominent trend in the recombinant protein market, with major companies focusing on developing cutting-edge products to enhance their market positions. For instance, ProteoGenix introduced the XtenCHO Transient CHO Expression System in March 2022, aiming to improve biologics development. This system offers significant advantages, including higher yields, optimized plasmid stability, and streamlined protocols for enhanced efficiency in bioanalytical applications and drug development.

Collaborations and partnerships are strategic initiatives undertaken by major companies in the recombinant protein market to gain a competitive edge. In October 2023, ARTES Biotechnology GmbH collaborated with Basic Pharma to establish a streamlined supply chain process for developing and producing non-GMP recombinant proteins. This collaboration focuses on expediting the time-to-market for new pharmaceutical products, showcasing the potential benefits of partnerships in fostering innovation.

In March 2022, Fujifilm, a Japan-based technology and manufacturing company, acquired Shenandoah Biotechnology for an undisclosed sum. The purpose of this acquisition is to enhance Fujifilm's position as a key partner for pharmaceutical clients in the growing advanced therapies market by providing a comprehensive source of cGMP cell culture solutions. Shenandoah Biotechnology, a U.S.-based biotechnology company, specializes in producing recombinant proteins, including cytokines and growth factors, which are essential for various life science applications such as drug discovery, research, and cell and gene therapies.

Major companies operating in the recombinant proteins market include Abcam plc, Abnova Corporation, Bio-Rad Laboratoroies Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Randox Laboratories Ltd., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Eli Lilly and Company.

North America was the largest region in the recombinant protein market in 2024. The regions covered in the recombinant proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Recombinant proteins are proteins that have been altered or edited using recombinant DNA technology. In this process, a plasmid is employed, containing the gene encoding the desired target protein, which is cloned downstream of a promoter region. These modified proteins find application in various fields, including pharmaceuticals, protein-based polymers for drug delivery, disease treatment through antibodies and enzymes, protein scaffolds for tissue engineering, and numerous other uses.

The primary types of recombinant protein products encompass antibodies, cytokines, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Antibodies, for example, are immune system components that circulate in the blood, identifying and neutralizing foreign objects such as bacteria and viruses. They are utilized across diverse applications, including drug and discovery development, therapeutics, research, and more. These recombinant proteins are predominantly utilized by pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and other relevant entities.

The recombinant proteins market research report is one of a series of new reports that provides recombinant proteins market statistics, including recombinant proteins industry global market size, regional shares, competitors with a recombinant proteins market share, detailed recombinant proteins market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant proteins industry. The recombinant proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The recombinant protein market consists of sales of recombinant monoclonal antibodies, interferons, and interleukins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.